Every prescription weight loss medication ranked by effectiveness, cost, side effects, and access — incorporating the Wegovy pill launch, new pricing programs, and the compounding crackdown.
Tirzepatide (Zepbound) remains the most effective weight loss medication with 20–22.5% average body weight loss. But 2026's biggest story is access: the Wegovy pill at $149/month, orforglipron approaching FDA approval, and TrumpRx.gov offering brand-name GLP-1s starting at ~$250–350/month are making these medications reachable for millions more Americans.
The weight loss medication landscape in 2026 looks nothing like it did even a year ago. A GLP-1 pill outsold every expectation with roughly 400,000 Americans taking it within 10 weeks of launch. A second oral GLP-1 — one you can take with food, at any time of day — is on the verge of FDA approval. Brand-name injectable prices have dropped by 30–60% through manufacturer programs. And the FDA has moved decisively against compounded versions, sending thousands of warning letters and referring at least one major telehealth company to the Department of Justice.
For patients, this means more options at lower prices — but also more complexity. This ranking cuts through the noise with a framework weighted across four dimensions: clinical effectiveness (40%), monthly cost and access (25%), side effect profile and tolerability (20%), and long-term sustainability (15%).
Tirzepatide delivers the highest weight loss of any approved medication. The SURMOUNT-5 head-to-head trial showed tirzepatide at 20.2% body weight loss vs. semaglutide at 13.7% — a decisive margin. For a 250-lb person, that translates to roughly 50–56 lbs vs. 34 lbs. Eli Lilly's self-pay pricing through LillyDirect starts at $199/month for the lowest dose, with the maintenance dose at $449/month. Zepbound also holds FDA approvals for obstructive sleep apnea and carries strong cardiometabolic benefit data.
Best for: Patients who need maximum weight loss, especially those with sleep apnea, type 2 diabetes, or significant cardiometabolic risk.
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events — making Wegovy the only weight loss medication with proven heart protection. Novo Nordisk's self-pay program through NovoCare runs $349/month (with $199/month for the first two months). The upcoming list price reduction to $675/month effective January 2027 should expand insurance coverage significantly. A larger clinical evidence base than any competitor gives physicians and patients the most data to work with.
Best for: Patients with cardiovascular disease or high cardiovascular risk. The strongest safety and outcomes data of any weight loss drug.
Approved December 22, 2025, the Wegovy pill is 2026's most transformative development. The OASIS 4 trial showed 13.6% mean weight loss (intent-to-treat) and 16.6% among adherent participants — comparable to the injection. With approximately 400,000 Americans now taking it just 10 weeks after launch, demand has outpaced every prior GLP-1 introduction. Pricing starts at $149/month for the starting dose (1.5 mg) through NovoCare. The tradeoff: it must be taken daily on an empty stomach, with only water, followed by a 30-minute fast before food or other medications.
Best for: Needle-averse patients who want GLP-1 effectiveness. The most affordable GLP-1 entry point for self-pay patients.
Eli Lilly's oral GLP-1 orforglipron is expected to receive FDA approval by mid-2026. Unlike the Wegovy pill, orforglipron can be taken at any time of day, with or without food — a significant convenience advantage. Phase 3 ATTAIN-1 results showed 7.5–11.2% weight loss at 72 weeks for patients without diabetes. Self-pay pricing is expected to start at $149 for the lowest dose, up to $399 through LillyDirect. Not yet included in our ranking because it lacks FDA approval, but it could reshape the oral GLP-1 market upon launch.
Generic Qsymia (available since May 2025) has quietly become one of 2026's best values. It combines the appetite suppression of phentermine with topiramate's satiety effects, producing 7–10% body weight loss — roughly double what phentermine achieves alone, and at a fraction of GLP-1 cost. The catch: topiramate carries teratogenicity risk (absolutely contraindicated in pregnancy), and cognitive side effects ("brain fog," word-finding difficulty) affect some patients. Still, for patients who can't afford or access GLP-1s, generic Qsymia offers the best cost-per-pound-lost ratio on the market.
Best for: Budget-conscious patients who want more than phentermine but aren't ready for GLP-1 pricing. Excellent as a "bridge" medication.
Contrave targets the brain's reward pathways rather than gut hormones, making it uniquely effective for emotional and reward-driven eaters. The naltrexone component reduces food cravings while bupropion (also the active ingredient in Wellbutrin) provides mild appetite suppression and mood support. The CurAccess program offers Contrave at $99/month. Weight loss is modest at 5–6%, but for patients whose overeating is driven by stress, emotional triggers, or food addiction patterns, Contrave addresses the root mechanism that GLP-1s may not reach.
Best for: Emotional eaters, patients with concurrent depression, patients who want to avoid injection-based treatment, or those who need a non-GLP-1 option.
Still the most-prescribed weight loss medication in America with roughly 740,000 monthly prescriptions, phentermine is cheap, widely available, and works fast. The problem: it's FDA-approved for only 12 weeks of use (though many physicians prescribe it longer off-label), it's a Schedule IV controlled substance, and it doesn't address the biological mechanisms that maintain obesity long-term. Average weight loss of 5–7% is roughly one-third what GLP-1s deliver. Most patients who start phentermine eventually transition to a GLP-1 for sustained results.
Best for: Short-term jumpstart while awaiting GLP-1 access or insurance approval, or patients who need the cheapest possible option.
At $4/month with a GoodRx coupon, metformin is the cheapest option on this list. It's FDA-approved for type 2 diabetes, not weight loss, but produces modest weight loss of 2–6% — particularly in patients with insulin resistance, PCOS, or prediabetes. A 2024 study linked metformin to the same anti-hunger molecular pathway activated by exercise. Weight loss is small but the safety profile is outstanding after 60+ years of clinical use, and it pairs well with GLP-1 medications for patients with metabolic syndrome.
Best for: Patients with prediabetes or insulin resistance who want metabolic improvement at minimal cost. Often used alongside a GLP-1 for additive benefit.
Orlistat blocks roughly 30% of dietary fat absorption. The OTC version (Alli, 60 mg) produces modest weight loss. The prescription version (Xenical, 120 mg) is slightly more effective. Both come with the well-known GI side effects — oily stools, flatulence, and urgent bowel movements when consuming high-fat meals. These side effects are so unpleasant that orlistat essentially forces behavioral change around fat intake. In the era of GLP-1 medications, orlistat has become a niche option, primarily useful for patients who cannot or will not take systemic medications.
Best for: Patients who want a non-systemic option (orlistat works only in the gut), or as a mild adjunct to other approaches.
| Medication | Weight Loss | Monthly Cost | Format | Duration |
|---|---|---|---|---|
| Tirzepatide | 20–22.5% | $199–449 | Weekly injection | Long-term |
| Wegovy (injection) | 15–17% | $199–349 | Weekly injection | Long-term |
| Wegovy (pill) | ~15% | $149–299 | Daily pill | Long-term |
| Qsymia (generic) | 7–10% | $50–100 | Daily pill | Long-term* |
| Contrave | 5–6% | $99–200 | Daily pill | Long-term |
| Phentermine | 5–7% | $10–50 | Daily pill | 12 weeks* |
| Metformin | 2–6% | $4–20 | Daily pill | Long-term |
| Orlistat | 3–5% | $30–60 | With meals | Long-term |
*Phentermine is FDA-approved for 12 weeks; many clinicians prescribe longer off-label. Qsymia has no formal duration limit but requires monitoring.
Three shifts have fundamentally reshaped this ranking compared to 2025.
The Wegovy pill's December 2025 approval was expected. Its adoption speed was not. Roughly 400,000 Americans are now taking it — more than were on injectable Wegovy at the same post-launch timepoint. Priced at $149/month for the starting dose, it represents the most accessible GLP-1 entry point ever. And orforglipron, expected by mid-2026, will remove even the empty-stomach requirement. Goldman Sachs projects oral GLP-1s will capture 24% ($22 billion) of the anti-obesity drug market by 2030.
Self-pay prices for brand-name GLP-1s have dropped dramatically. Wegovy went from a list price above $1,300/month to a self-pay option at $199–349. Zepbound is available starting at $199 through LillyDirect. TrumpRx.gov connects patients to manufacturer pricing at $250–350/month for injectables and $149 for GLP-1 pills. Novo Nordisk's incoming list price reduction to $675/month effective January 2027 should further expand insurance coverage. The era of GLP-1s as exclusively luxury medications is ending.
The FDA has moved aggressively against compounded GLP-1 products since the semaglutide shortage resolution in February 2025. In February 2026, the agency announced its intent to "take decisive steps" to restrict GLP-1 active pharmaceutical ingredients for compounders, while the HHS General Counsel referred Hims & Hers to the Department of Justice. By March 2026, the FDA had sent warning letters to more than 30 telehealth companies. Patients on compounded semaglutide should evaluate transitioning to brand-name products, which are now priced competitively with many compounded alternatives.
One of the most streamlined telehealth GLP-1 programs available. Transparent pricing with no hidden fees. Both semaglutide and tirzepatide available.
Check Eligibility →If maximum weight loss is the priority and budget allows: tirzepatide (Zepbound). The head-to-head data is clear — 20%+ vs. 14% for semaglutide.
If you have heart disease or high cardiovascular risk: injectable semaglutide (Wegovy). The SELECT trial's 20% MACE reduction is unmatched by any other weight loss medication.
If needles are a dealbreaker: the Wegovy pill is the current best oral option. Wait for orforglipron if you want a pill without the empty-stomach restrictions.
If budget is the primary constraint: generic Qsymia ($50–100/month) offers the best effectiveness-per-dollar. Phentermine ($10–50) is cheapest but short-term. Metformin ($4–20) is best for patients with insulin resistance.
If emotional eating is the driver: Contrave targets reward pathways in a way GLP-1s don't. It may work better for patients whose obesity is rooted in stress-driven or compulsive eating patterns.
Combines GLP-1 medication with behavioral coaching for patients who want structured support alongside their prescription.
Check Eligibility →The pipeline suggests 2026's ranking will shift significantly by 2027. Retatrutide, Eli Lilly's triple-agonist (GLP-1 + GIP + glucagon), delivered 28.7% body weight loss in Phase 3 — roughly 71 lbs on average — and seven more Phase 3 readouts are expected throughout 2026. CagriSema (semaglutide + amylin analog) showed 22.7% loss with an FDA filing expected in 2026. Bimagrumab, a muscle-preserving approach, produced 22.1% total weight loss with 93% of it being fat when combined with semaglutide. These next-generation therapies could push the effectiveness ceiling above 30% body weight loss within the next two years.
This ranking covers FDA-approved medications only. Compounded semaglutide and tirzepatide are not FDA-approved finished products and face increasing regulatory enforcement in 2026. The FDA has stated that compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug." With brand-name prices now closer to compounded alternatives, patients should discuss FDA-approved options with their provider. See our full guide to the 2026 compounding crackdown.
Roughly 12.4% of Americans — more than 30 million people — are now using GLP-1 medications for weight loss. If you meet the eligibility criteria (BMI ≥30 or BMI ≥27 with a weight-related health condition), the path has never been more straightforward. Telehealth platforms have streamlined the process to an online consultation, lab review, and doorstep delivery, often within days.
Transparent pricing across GLP-1 weight loss programs. Convenient online consultations with licensed providers.
Check Eligibility →